Enzymatica (EN9) Stock Overview
A life science company, develops and sells medical devices for infection-related diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
EN9 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Enzymatica AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.14 |
| 52 Week High | SEK 0.42 |
| 52 Week Low | SEK 0.10 |
| Beta | 0.35 |
| 1 Month Change | -6.21% |
| 3 Month Change | -2.71% |
| 1 Year Change | 19.58% |
| 3 Year Change | -42.14% |
| 5 Year Change | -90.14% |
| Change since IPO | -91.56% |
Recent News & Updates
Recent updates
Shareholder Returns
| EN9 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 4.4% | -0.09% | 0.9% |
| 1Y | 19.6% | 23.6% | 7.3% |
Return vs Industry: EN9 underperformed the German Pharmaceuticals industry which returned 25.4% over the past year.
Return vs Market: EN9 exceeded the German Market which returned 7.3% over the past year.
Price Volatility
| EN9 volatility | |
|---|---|
| EN9 Average Weekly Movement | 11.2% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in DE Market | 14.5% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: EN9's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: EN9's weekly volatility has decreased from 21% to 11% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 21 | Sana Alajmovic | www.enzymatica.com |
Enzymatica AB (publ), a life science company, develops and sells medical devices for infection-related diseases. The company’s product includes ColdZyme, a mouth spray that protects against the upper respiratory viruses that can cause cold and flu symptoms. It also provides enzyme formulations for skin care.
Enzymatica AB (publ) Fundamentals Summary
| EN9 fundamental statistics | |
|---|---|
| Market cap | €45.50m |
| Earnings (TTM) | -€4.86m |
| Revenue (TTM) | €5.05m |
Is EN9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EN9 income statement (TTM) | |
|---|---|
| Revenue | SEK 53.90m |
| Cost of Revenue | SEK 20.78m |
| Gross Profit | SEK 33.13m |
| Other Expenses | SEK 85.02m |
| Earnings | -SEK 51.89m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Apr 14, 2026
| Earnings per share (EPS) | -0.21 |
| Gross Margin | 61.45% |
| Net Profit Margin | -96.27% |
| Debt/Equity Ratio | 0.006% |
How did EN9 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/19 09:51 |
| End of Day Share Price | 2026/02/19 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Enzymatica AB (publ) is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jakob Lembke | ABG Sundal Collier Sponsored |
| Gustaf Meyer | Redeye |